Euthymics Bioscience http://euthymics.com A Neuroscience-Focused, Clinical Stage Company Wed, 16 May 2012 15:02:34 +0000 en hourly 1 http://wordpress.org/?v=3.1 Euthymics Bioscience Fact Sheet http://euthymics.com/corporate-fact-sheet/euthymics-bioscience-fact-sheet/ http://euthymics.com/corporate-fact-sheet/euthymics-bioscience-fact-sheet/#comments Wed, 04 Apr 2012 18:46:13 +0000 admin http://euthymics.com/?p=349 ]]> EUTHYMICS® BIOSCIENCE, INC. IS A NEUROSCIENCE-FOCUSED CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS. The company’s lead product candidate amitifadine (formerly EB-1010) for depression is a serotonin-preferring triple reuptake inhibitor that acts on serotonin, norepinephrine and dopamine in a specific ratio and is given as monotherapy (a single capsule). Amitifadine has demonstrated proof-of-concept efficacy as treatment for major depression without causing associated weight gain or loss of sexual function, which often lead to poor adherence to standard antidepressants. Euthymics also is developing a second triple reuptake inhibitor (EB-1020) for adult ADHD that acts on serotonin, norepinephrine and dopamine in a different ratio. EB-1020 is in a Phase 1 clinical trial. Euthymics is a private corporation with headquarters in Cambridge, Massachusetts.
Euthymics Bioscience Fact Sheet

]]> http://euthymics.com/corporate-fact-sheet/euthymics-bioscience-fact-sheet/feed/ 0 Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD) http://euthymics.com/press-releases/euthymics-bioscience-inc-initiates-clinical-trial-for-new-drug-targeted-for-adult-attention-deficit-hyperactivity-disorder-adhd/ http://euthymics.com/press-releases/euthymics-bioscience-inc-initiates-clinical-trial-for-new-drug-targeted-for-adult-attention-deficit-hyperactivity-disorder-adhd/#comments Thu, 22 Mar 2012 12:00:00 +0000 admin http://euthymics.com/?p=466 ]]> Euthymics Bioscience, Inc. today announced that it has initiated a Phase 1 clinical trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder (ADHD), with low risk of drug abuse liability.

 

Press Release-EB-1020_Phase1_FINAL2

 

]]> http://euthymics.com/press-releases/euthymics-bioscience-inc-initiates-clinical-trial-for-new-drug-targeted-for-adult-attention-deficit-hyperactivity-disorder-adhd/feed/ 0 Clinical investigator Dr. Donald Garcia discusses the TRIADE study on Austin’s NBC affiliate KXAN http://euthymics.com/in-the-news/february-22nd-clinical-investigator-dr-donald-garcia-discusses-the-triade-study-on-austin%e2%80%99s-nbc-affiliate-kxan/ http://euthymics.com/in-the-news/february-22nd-clinical-investigator-dr-donald-garcia-discusses-the-triade-study-on-austin%e2%80%99s-nbc-affiliate-kxan/#comments Wed, 22 Feb 2012 18:01:21 +0000 admin http://euthymics.com/?p=453 ]]> February 22, 2012 – Clinical investigator Dr. Donald Garcia discusses the TRIADE study on Austin’s NBC affiliate KXAN

]]> http://euthymics.com/in-the-news/february-22nd-clinical-investigator-dr-donald-garcia-discusses-the-triade-study-on-austin%e2%80%99s-nbc-affiliate-kxan/feed/ 0 Clinical investigator Dr. Ronald Fuchs discusses TRIADE and amitifadine on Philadelphia’s 6 ABC http://euthymics.com/in-the-news/clinical-investigator-dr-ronald-fuchs-discusses-triade-and-amitifadine-on-philadelphia%e2%80%99s-6-abc/ http://euthymics.com/in-the-news/clinical-investigator-dr-ronald-fuchs-discusses-triade-and-amitifadine-on-philadelphia%e2%80%99s-6-abc/#comments Wed, 15 Feb 2012 18:14:55 +0000 admin http://euthymics.com/?p=446 ]]> February 15, 2012 – Clinical investigator Dr. Ronald Fuchs discusses TRIADE and amitifadine on Philadelphia’s 6 ABC

]]> http://euthymics.com/in-the-news/clinical-investigator-dr-ronald-fuchs-discusses-triade-and-amitifadine-on-philadelphia%e2%80%99s-6-abc/feed/ 0 TRIADE clinical investigator Dr. Riaz Baber discusses the trial and amitifadine in the Naperville Sun http://euthymics.com/in-the-news/triade-clinical-investigator-dr-riaz-baber-discusses-the-trial-and-amitifadine-in-the-naperville-sun/ http://euthymics.com/in-the-news/triade-clinical-investigator-dr-riaz-baber-discusses-the-trial-and-amitifadine-in-the-naperville-sun/#comments Tue, 07 Feb 2012 18:29:01 +0000 admin http://euthymics.com/?p=434 February 7th, 2012 – Click here to view

]]> http://euthymics.com/in-the-news/triade-clinical-investigator-dr-riaz-baber-discusses-the-trial-and-amitifadine-in-the-naperville-sun/feed/ 0 Dr. Michael Downing, TRIADE clinical investigator, discusses depression and amitifadine on Dallas’ DFW Closeup http://euthymics.com/in-the-news/dr-michael-downing-triade-clinical-investigator-discusses-depression-and-amitifadine-on-dallas%e2%80%99-dfw-closeup/ http://euthymics.com/in-the-news/dr-michael-downing-triade-clinical-investigator-discusses-depression-and-amitifadine-on-dallas%e2%80%99-dfw-closeup/#comments Sun, 15 Jan 2012 18:14:19 +0000 admin http://euthymics.com/?p=426 January 15, 2012 – Click here to view

]]> http://euthymics.com/in-the-news/dr-michael-downing-triade-clinical-investigator-discusses-depression-and-amitifadine-on-dallas%e2%80%99-dfw-closeup/feed/ 0 TRIADE investigator Dr. Eugene DuBoff discusses depression and Euthymics’ amitifadine in The Denver Post http://euthymics.com/in-the-news/triade-investigator-dr-eugene-duboff-discusses-depression-and-euthymics%e2%80%99-amitifadine-in-the-denver-post/ http://euthymics.com/in-the-news/triade-investigator-dr-eugene-duboff-discusses-depression-and-euthymics%e2%80%99-amitifadine-in-the-denver-post/#comments Tue, 13 Dec 2011 22:13:20 +0000 admin http://euthymics.com/?p=421 December 12, 2011 - Click here to view

 

]]> http://euthymics.com/in-the-news/triade-investigator-dr-eugene-duboff-discusses-depression-and-euthymics%e2%80%99-amitifadine-in-the-denver-post/feed/ 0 Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 Into Clinical Trials For Adult ADHD http://euthymics.com/press-releases/euthymics-bioscience-inc-presents-data-that-supports-advancing-eb-1020-into-clinical-trials-for-adult-adhd/ http://euthymics.com/press-releases/euthymics-bioscience-inc-presents-data-that-supports-advancing-eb-1020-into-clinical-trials-for-adult-adhd/#comments Wed, 07 Dec 2011 12:32:00 +0000 admin http://euthymics.com/?p=382 ]]> Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 Into Clinical Trials For Adult ADHD.

 

EB-1020_ACNP_120611_FINAL.pdf

 

]]> http://euthymics.com/press-releases/euthymics-bioscience-inc-presents-data-that-supports-advancing-eb-1020-into-clinical-trials-for-adult-adhd/feed/ 0 Euthymics Featured in BioCentury Emerging Company Profile http://euthymics.com/press-releases/december-5th-euthymics-featured-in-biocentury-emerging-company-profile/ http://euthymics.com/press-releases/december-5th-euthymics-featured-in-biocentury-emerging-company-profile/#comments Mon, 05 Dec 2011 17:42:04 +0000 admin http://euthymics.com/?p=391 December 5, 2011  -

Emerging Company Profile – Euthymics: Balancing Act

 

 

]]> http://euthymics.com/press-releases/december-5th-euthymics-featured-in-biocentury-emerging-company-profile/feed/ 0 TRIADE clinical trial investigator Dr. Kashinath Yadalam discusses TRIADE and Euthymics’ amitifadine on Lake Charles, LA’s KPLC http://euthymics.com/in-the-news/triade-clinical-trial-investigator-dr-kashinath-yadalam-discusses-triade-and-euthymics%e2%80%99-amitifadine-on-lake-charles-la%e2%80%99s-kplc/ http://euthymics.com/in-the-news/triade-clinical-trial-investigator-dr-kashinath-yadalam-discusses-triade-and-euthymics%e2%80%99-amitifadine-on-lake-charles-la%e2%80%99s-kplc/#comments Wed, 23 Nov 2011 21:57:39 +0000 admin http://euthymics.com/?p=404 November 23, 2011 - Click here to view

]]> http://euthymics.com/in-the-news/triade-clinical-trial-investigator-dr-kashinath-yadalam-discusses-triade-and-euthymics%e2%80%99-amitifadine-on-lake-charles-la%e2%80%99s-kplc/feed/ 0